Pierson, Ransdell

Follow Pierson, Ransdell: Website |


CMS wants new study of Lilly’s Alzheimer’s test before reconsidering Medicare coverage

CMS wants new study of Lilly’s Alzheimer’s test before reconsidering Medicare coverage

October 1, 2013 3:32 pm by | 0 Comments

(Reuters) – Eli Lilly and Co on Monday said the federal government has unfairly blocked patient access to its Amyvid diagnostic test for Alzheimer’s disease by denying reimbursement for such products, and said a requested new study of the test could c…


Researchers study “super responders” to figure out which cancer drugs can help which patients

Researchers study “super responders” to figure out which cancer drugs can help which patients

September 15, 2013 4:00 pm by | 0 Comments

Armed with huge advances in genetic sequencing technology and growing knowledge of the genetic underpinnings of cancer, a handful of top academic centers are taking a new look at outlier patients.



Closely watched Bristol-Myers drug Yervoy fails in prostate cancer study

Closely watched Bristol-Myers drug Yervoy fails in prostate cancer study

September 12, 2013 4:09 am by | 0 Comments

(Reuters) – Bristol-Myers Squibb Co’s immunotherapy drug Yervoy failed to significantly prolong survival among patients with advanced prostate cancer who had previously received chemotherapy, according to limited data from the first late-stage study o…


Lilly may not beat the odds in Alimta patent battle but it’s not going down without a fight

Lilly may not beat the odds in Alimta patent battle but it’s not going down without a fight

August 19, 2013 1:02 pm by | 0 Comments

(Reuters) – Eli Lilly and Co, now facing one of the worst patent cliffs in its history, could find $15 billion in sorely needed relief if it beats the odds and wins a closely watched patent battle with generic drugmaker Teva Pharmaceutical Industries …


Lilly beats forecast with costs cuts and strong sales of Cymbalta

Lilly beats forecast with costs cuts and strong sales of Cymbalta

July 24, 2013 6:43 am by | 0 Comments

(Reuters) – Eli Lilly and Co reported higher-than-expected quarterly earnings, helped by cost cuts and strong sales of Cymbalta, a depression treatment that will lose patent protection by year end, and the drugmaker raised its full-year profit forecas…


J&J continues to build prostate cancer portfolio with $1B Aragon deal

J&J continues to build prostate cancer portfolio with $1B Aragon deal

June 17, 2013 8:16 am by | 0 Comments

(Reuters) – Johnson & Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, bolstering J&J’s role in the field after it acquired another experimental prostate-cancer treatment fou…


Report identifies 300 medical devices at risk of cyber attacks

Report identifies 300 medical devices at risk of cyber attacks

June 13, 2013 7:49 pm by | 0 Comments

(Reuters) – The U.S. Food and Drug Administration on Thursday urged medical device makers and medical facilities to upgrade security protections to protect against potential cyber threats that could compromise the devices or patient privacy.
It releas…



AbbVie hepatitis C 5-drug combo knocks out virus at eight weeks in 96% of patients

AbbVie hepatitis C 5-drug combo knocks out virus at eight weeks in 96% of patients

April 23, 2013 6:05 am by | 0 Comments

(Reuters) – A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.
The latest …


FDA advisory panel to reconsider safety of diabetes drug Avandia

FDA advisory panel to reconsider safety of diabetes drug Avandia

April 12, 2013 5:19 pm by | 0 Comments

(Reuters) – A federal health advisory panel in June will reconsider safety data on GlaxoSmithKline Plc’s Avandia diabetes drug, although the British drugmaker on Friday said it has not sought permission to make the nearly discontinued drug widely avai…


J&J beats forecast, but 2013 view lags expectations

J&J beats forecast, but 2013 view lags expectations

January 22, 2013 8:00 am by | 0 Comments

(Reuters) – Johnson & Johnson reported better-than-expected fourth-quarter earnings on Tuesday, but took another big special charge for its recalled artificial hips and forecast 2013 earnings below Wall Street forecasts.
The diversified healthcare…


Alimta patent lawsuit may be Lilly’s $15B lifeline

Alimta patent lawsuit may be Lilly’s $15B lifeline

January 4, 2013 12:04 am by | 0 Comments

NEW YORK (Reuters) – Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit.
Should an obscure patent on Lilly lung cancer drug Alimta survive a court challenge this year, the compa…


Lilly’s Lundberg: It’s no longer “if” but “when” in race to find Alzheimer’s treatment

Lilly’s Lundberg: It’s no longer “if” but “when” in race to find Alzheimer’s treatment

December 11, 2012 3:47 pm by | 0 Comments

(Reuters) – Drugmaker Eli Lilly & Co is confident it will do for Alzheimer’s patients what it did almost a century ago for diabetics – find a breakthrough treatment, even though skeptics say it could take years.
“We are on the cusp here of writing…


Lilly trials boost amyloid-protein link to Alzheimer’s-analysis

Lilly trials boost amyloid-protein link to Alzheimer’s-analysis

October 29, 2012 4:23 pm by | 0 Comments

(Reuters) – Levels of a protein believed to be a main cause of Alzheimer’s disease rose in the blood of patients treated with Eli Lilly’s experimental drug in late-stage trials, suggesting the protein, beta amyloid, was removed from the brain as inten…